Fiduciary Trust Co Has $4.49 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Fiduciary Trust Co reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 34.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,885 shares of the company's stock after selling 4,666 shares during the quarter. Fiduciary Trust Co's holdings in IDEXX Laboratories were worth $4,489,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Eads & Heald Wealth Management lifted its stake in IDEXX Laboratories by 0.8% during the second quarter. Eads & Heald Wealth Management now owns 2,686 shares of the company's stock worth $1,309,000 after purchasing an additional 22 shares during the period. LRI Investments LLC boosted its stake in IDEXX Laboratories by 21.7% in the 2nd quarter. LRI Investments LLC now owns 129 shares of the company's stock valued at $63,000 after buying an additional 23 shares in the last quarter. Sovereign Financial Group Inc. grew its position in IDEXX Laboratories by 5.1% in the third quarter. Sovereign Financial Group Inc. now owns 470 shares of the company's stock valued at $237,000 after acquiring an additional 23 shares during the period. Mather Group LLC. raised its stake in IDEXX Laboratories by 3.9% during the third quarter. Mather Group LLC. now owns 617 shares of the company's stock worth $312,000 after acquiring an additional 23 shares in the last quarter. Finally, Angeles Wealth Management LLC lifted its holdings in shares of IDEXX Laboratories by 2.4% during the third quarter. Angeles Wealth Management LLC now owns 1,078 shares of the company's stock valued at $545,000 after acquiring an additional 25 shares during the period. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Trading Down 0.0 %

Shares of IDXX traded down $0.01 during trading hours on Friday, hitting $421.75. 338,607 shares of the stock traded hands, compared to its average volume of 505,750. The business has a fifty day moving average of $451.91 and a 200-day moving average of $478.11. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $34.53 billion, a PE ratio of 40.67, a price-to-earnings-growth ratio of 3.68 and a beta of 1.36. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.69 by $0.11. The company had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company's revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.53 EPS. Analysts expect that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Barclays dropped their target price on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating for the company in a research report on Monday, November 4th. StockNews.com raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Thursday. JPMorgan Chase & Co. reduced their target price on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a report on Friday, October 11th. Stifel Nicolaus dropped their price target on IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a report on Thursday, October 10th. Finally, Piper Sandler reissued a "neutral" rating and issued a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $552.38.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.